BioLine RX Ltd (BLRX) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.108x

Based on the latest financial reports, BioLine RX Ltd (BLRX) has a cash flow conversion efficiency ratio of -0.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.11 Million ≈ $-5.65K USD) by net assets (ILA19.53 Million ≈ $52.37K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

BioLine RX Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)

This chart illustrates how BioLine RX Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BioLine RX Ltd debt and liabilities for a breakdown of total debt and financial obligations.

BioLine RX Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioLine RX Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Wong Engineering Corporation Bhd KLSE:7050	-0.012x
Transocean Holdings Bhd KLSE:7218	-0.015x
Paratech Company Limited KQ:033540	-0.044x
Burford Capital Limited LSE:BUR	0.048x
PHOENIX NEW MED.ADR 1/48 F:1PX	N/A
Robin Energy Ltd. NASDAQ:RBNE	-0.037x
Fountain BR:FOU	0.287x
Magna Polonia SA WAR:06N	-0.007x

Annual Cash Flow Conversion Efficiency for BioLine RX Ltd (2010–2024)

The table below shows the annual cash flow conversion efficiency of BioLine RX Ltd from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see BLRX market cap overview.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	ILA13.46 Million ≈ $36.09K	ILA-43.87 Million ≈ $-117.62K	-3.259x	-90.63%
2023-12-31	ILA13.22 Million ≈ $35.45K	ILA-22.61 Million ≈ $-60.61K	-1.710x	-231.27%
2022-12-31	ILA50.84 Million ≈ $136.30K	ILA-26.24 Million ≈ $-70.35K	-0.516x	-49.07%
2021-12-31	ILA68.09 Million ≈ $182.54K	ILA-23.57 Million ≈ $-63.20K	-0.346x	+67.13%
2020-12-31	ILA22.03 Million ≈ $59.06K	ILA-23.21 Million ≈ $-62.21K	-1.053x	-55.13%
2019-12-31	ILA33.38 Million ≈ $89.49K	ILA-22.67 Million ≈ $-60.77K	-0.679x	-15.98%
2018-12-31	ILA41.32 Million ≈ $110.78K	ILA-24.19 Million ≈ $-64.86K	-0.585x	-50.68%
2017-12-31	ILA52.88 Million ≈ $141.77K	ILA-20.55 Million ≈ $-55.09K	-0.389x	+6.22%
2016-12-31	ILA35.03 Million ≈ $93.91K	ILA-14.51 Million ≈ $-38.91K	-0.414x	-39.23%
2015-12-31	ILA47.61 Million ≈ $127.64K	ILA-14.17 Million ≈ $-37.98K	-0.298x	+34.72%
2014-12-31	ILA31.77 Million ≈ $85.16K	ILA-14.48 Million ≈ $-38.82K	-0.456x	+73.68%
2013-12-31	ILA11.68 Million ≈ $31.32K	ILA-20.23 Million ≈ $-54.25K	-1.732x	-28.90%
2012-12-31	ILA14.97 Million ≈ $40.14K	ILA-20.11 Million ≈ $-53.93K	-1.344x	-169.77%
2011-12-31	ILA22.53 Million ≈ $60.41K	ILA-11.22 Million ≈ $-30.09K	-0.498x	-673.33%
2010-12-31	ILA131.96 Million ≈ $353.78K	ILA11.46 Million ≈ $30.73K	0.087x	--

About BioLine RX Ltd

TA:BLRX Israel Biotechnology

Market Cap

$9.10 Million

ILA3.39 Billion ILA

Market Cap Rank

#27266 Global

#392 in Israel

Share Price

ILA1.30

Change (1 day)

-7.14%

52-Week Range

ILA1.20 - ILA3.70

All Time High

ILA618.30